Clinical trial Recruiting at 1 site Interventional Ages 15 to 40

Using AI and VR to help treat eating disorders

Official title: Assistance and Rehabilitation of Eating Behavior Through Devices Based on Artificial Intelligence and Virtual Reality

Run by Istituto per la Ricerca e l'Innovazione Biomedica · NCT06799962 · Data updated 2026-11-12

This study is testing new virtual reality tools powered by artificial intelligence to see if they can help people with eating disorders like anorexia and bulimia feel better faster than traditional therapy.

Quick facts

Study typeInterventional
Ages15 Years to 40 Years
SexAll
Enrollment80 (estimated)
SponsorIstituto per la Ricerca e l'Innovazione Biomedica
Academic / other
Locations1 site (Messina, Italy)
StatusRecruiting
StartedJanuary 30, 2025
Main results expectedJuly 30, 2025
Study endsJanuary 31, 2026
Registry record updatedApril 30, 2025
Trial IDNCT06799962 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals diagnosed with anorexia nervosa or bulimia nervosa, with a BMI between 16 and 32, and who have had the disorder for at least six months.

Probably not a fit

Patients with eating disorders who are currently undergoing other psychotherapeutic interventions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to develop innovative virtual reality (VR) devices combined with artificial intelligence (AI) to treat eating disorders such as anorexia nervosa and bulimia nervosa. The ARCADIA VR project focuses on creating personalized VR systems that offer unique therapeutic approaches, like Enhanced Body-Swap for anorexia and Emotional Rescripting for bulimia. These technologies are designed to improve the effectiveness and speed of treatment by monitoring patients' conditions and tailoring interventions to their needs. The study seeks to provide a new avenue for rehabilitation that goes beyond traditional cognitive behavioral therapy.

Why it matters

Potential benefit: If successful, this approach could lead to more effective and faster rehabilitation for patients with eating disorders.

How similar studies have gone: While the use of VR and AI in treating eating disorders is a novel approach, similar studies in other areas of mental health have shown promising results.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Clinical diagnosis of Anorexia Nervosa or Bulimia Nervosa according to DSM-5-TR (APA, 2013) and ICD-11, confirmed by a public hospital setting
* Body Mass Index (BMI) between 16 and 32
* Disorder present for at least 6 months
* No other concurrent psychotherapeutic interventions during the study
* All participants with a previous diagnosis will be re-evaluated and confirmed through assessment and consent by expert professionals in the research team (i.e., a neuropsychiatrist and a clinical psychologist)

Where it's running

  • Institute for Biomedical Research and Innovation (IRIB) - National Research Council (CNR)
    Messina, Italy, Italy
    Recruiting

Study contacts

  • Principal investigator: Flavia Marino — Institute for Biomedical Research and Innovation (IRIB) - National Research Council (CNR)
  • Study coordinator: Flavia marino
  • Email: flavia.marino@irib.cnr.it
  • Phone: +393395798263

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.